Capricor Therapeutics Inc...

NASDAQ: CAPR · Real-Time Price · USD
14.17
0.99 (7.51%)
At close: Jun 06, 2025, 1:58 PM
7.51%
Bid 14.15
Market Cap 647.68M
Revenue (ttm) 17.36M
Net Income (ttm) -55.06M
EPS (ttm) -1.37
PE Ratio (ttm) -10.34
Forward PE -23.21
Analyst Buy
Ask 14.17
Volume 1,515,872
Avg. Volume (20D) 2,067,055
Open 13.10
Previous Close 13.18
Day's Range 12.80 - 14.34
52-Week Range 3.52 - 23.40
Beta 0.85

About CAPR

undefined

Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CAPR
Website n/a
Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CAPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts
1 month ago
-29.13%
Shares of vaccine and gene therapy stocks are trad... Unlock content with Pro Subscription
1 month ago
-13.15%
Capricor Therapeutics shares are trading lower. The company announced the completion of a mid-cycle review meeting with the FDA for the Company's Biologics License Application seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy cardiomyopathy.